University of British Columbia

8 articles with University of British Columbia

• Eyam Acquires Option for Novel Antibody Biologic Therapeutics for the Treatment of Leukemia and Lymphoma

  9/27/2022

  Eyam Vaccines and Immunotherapeutics (Eyam), has announced the acquisition of a new Option to license the patents related to an antibody biologic cancer therapeutic from the University of British Columbia (UBC).

• Eyam Vaccines And Immunotherapeutics Embarks On New Licensing Agreement For Creating Innovative Vaccine Technologies

  8/3/2022

  Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and the James Hutton Institute (JHI).

• 

  Researchers Stumble Upon Potential Key to Slow DMD

  7/5/2022

  Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
• 

  Research Roundup: Vitamin D Deficiency and Severe COVID-19

  2/11/2022

  Recent research supports a link between vitamin D deficiency and severe COVID-19. Here’s a look. 
• 

  Research Roundup: A Complete Human Genome Sequenced and More

  6/4/2021

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

• Repeat: Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

  4/26/2021

  Core One Labs Inc., is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with the University of British Columbia.

• Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC

  4/24/2021

  Core One Labs Inc., is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with the University of British Columbia.

• MYND Life Sciences Inc. Announces Collaborative Research Agreement with the University of British Columbia on Major Depressive Disorder

  2/2/2021

  MYND Life Sciences Inc. a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce it has signed a Collaborative Research Agreement with the University of British Columbia focussing on Major Depressive Disorder, often referred to as depression.